BMY - Bristol-Myers Squibb Company
| Previous close | 66.38 |
| Open | 66.51 |
| Bid | 66.14 x 800 |
| Ask | 66.15 x 900 |
| Day's range | 66.00 - 66.96 |
| 52-week range | 42.48 - 68.34 |
| Volume | 3,963,179 |
| Avg. volume | 18,665,488 |
| Market cap | 155.185B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | 32.94 |
| EPS (TTM) | 2.01 |
| Earnings date | 22 Apr 2020 - 26 Apr 2020 |
| Forward dividend & yield | 1.80 (2.71%) |
| Ex-dividend date | 01 Jan 2020 |
| 1y target est | 73.40 |
- Business Wire
Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma
Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced...
- Business Wire
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Opdivo Plus Yervoy Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC
- Zacks
Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat
Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.
- Zacks
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
- Zacks
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review
Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
- Business Wire
Multinational Inflammatory Bowel Disease Survey Uncovers Striking Differences in Patients’ and Physicians’ Treatment Goals and Disease Management Expectations
Multinational IBDe Survey Uncovers Striking Differences in Patients’ and Physicians’ Treatment Goals and Disease Management Expectations
- Business Wire
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel), the company’s autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020.
- Zacks
The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies
The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies
- Zacks
Q4 Earnings Season Scorecard and Analyst Reports for Alibaba, Toyota & Others
Q4 Earnings Season Scorecard and Analyst Reports for Alibaba, Toyota & Others
- Zacks
What Makes DHT Holdings (DHT) a New Strong Buy Stock
DHT Holdings (DHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks
Radian (RDN) Upgraded to Buy: Here's Why
Radian (RDN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Fiat Chrysler (FCAU) Upgraded to Strong Buy: Here's Why
Fiat Chrysler (FCAU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade
AC Immune (ACIU) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
Bristol-Myers Squibb Company Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
It's been a good week for Bristol-Myers Squibb Company (NYSE:BMY) shareholders, because the company has just released...
- Zacks
This is Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
- Zacks
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
- Zacks
How Trading Your Own Retirement Can Fleece Your Financial Future - February 07, 2020
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
- Zacks
Can Biotech ETFs Continue to Soar in 2020?
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
- Zacks
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
- Zacks
Bristol-Myers Squibb (BMY) Surpasses Q4 Earnings and Revenue Estimates
Bristol-Myers (BMY) delivered earnings and revenue surprises of 38.64% and 29.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
- Investing.com
Bristol-Myers Squibb Earnings, Revenue Beat in Q4
Investing.com - Bristol-Myers Squibb (NYSE:BMY) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
